Advertisement
Advertisement
U.S. markets close in 4 hours 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0878+0.0878 (+2.20%)
As of 09:50AM EDT. Market open.
Advertisement

ImmunoPrecise Antibodies Ltd.

3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada

https://www.ipatherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees85

Key Executives

NameTitlePayExercisedYear Born
Dr. Jennifer Lynne Bath Ph.D.CEO, Pres & Non-Independent Director770.16kN/AN/A
Mr. Brad McConnChief Financial OfficerN/AN/AN/A
Mr. David E. OrtonChief Operating OfficerN/AN/AN/A
Dr. Ilse RoodinkChief Scientific OfficerN/AN/AN/A
Ms. Carla DahlVP of MarketingN/AN/AN/A
Dr. Barry Neil DuplantisVP of Client RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Corporate Governance

ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement